Cannabinoid Pico-Emulsion Using Polysorbate 80 for Injectable Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for cannabinoid delivery, such as smoking, vaping, and edibles, face limitations including respiratory issues, unpredictable potency, and reduced bioavailability due to first-pass metabolism, while injectable formulations offer precision but struggle to achieve stable emulsions in the picometer range, which could provide enhanced bioavailability and antibiotic properties.
Innovation Solution
A process involving high-purity cannabinoid isolates and a specific surfactant (polysorbate 80 with HLB 15) is used to create a stable cannabinoid pico-emulsion with micelles ranging from 4900 to 850 picometers, ensuring stability through precise surfactant saturation and sonication, followed by filtration for sterility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If legacy delivery methods (smoking, vaping, edibles) are used, then ease of administration is maintained, but bioavailability is reduced and respiratory harm occurs
Solution Approach 1:
The patent employs phase transition technology by creating an emulsion system where cannabinoids are dispersed in water through surfactant-mediated phase separation. The specific phase transition approach involves forming nanometer-scale droplets of oil-phase cannabinoids within an aqueous continuous phase, achieving high bioavailability without respiratory harm by eliminating combustion and vaporization processes
Solution Approach 2:
The invention uses composite material principles by combining multiple components (cannabinoids, surfactants, water, and co-surfactants) into a unified emulsion system. This composite approach allows the formulation to exhibit properties superior to individual components, including enhanced solubility, stability, and bioavailability while eliminating harmful effects of legacy delivery methods
2Ease of operation
If edibles are used, then discretion is improved, but onset time is delayed and potency is unpredictable
Solution Approach 1:
The emulsion formulation utilizes phase transition principles to create a pre-digested, bioavailable state of cannabinoids that can be rapidly absorbed. By transforming cannabinoids from an oil-phase insoluble state into water-phase dispersed droplets through surfactant mediation, the system eliminates the need for extensive gastrointestinal metabolism, enabling rapid onset comparable to injection while maintaining the discretion of oral administration
3Ease of manufacture
If THC is metabolized through first-pass metabolism, then delivery is simplified, but bioavailability decreases and metabolites remain longer
Solution Approach 1:
The patent applies phase transition technology to bypass first-pass metabolism by creating an emulsion system that delivers cannabinoids in a pre-absorbed, bioavailable state. The phase transition from oil to water dispersion creates droplets small enough to be rapidly absorbed directly into the bloodstream through the intestinal wall, effectively circumventing the liver's first-pass metabolism while maintaining simple oral delivery
Solution Approach 2:
The surfactant acts as an intermediary substance that facilitates the interaction between oil-phase cannabinoids and water-phase absorption mechanisms. This intermediary enables the cannabinoids to traverse the gastrointestinal barrier without requiring extensive metabolic processing, directly entering systemic circulation and bypassing first-pass metabolism while maintaining delivery simplicity
4Reliability
If injectable formulations are used, then bioavailability is enhanced, but achieving stable picometer-range emulsions is difficult
Solution Approach 1:
The invention employs parameter change principles by systematically optimizing multiple formulation parameters including surfactant concentration, droplet size distribution, pH, ionic strength, and temperature. These parameter adjustments create a thermodynamically stable emulsion system where nanometer-scale droplets remain dispersed without aggregation, achieving both the picometer-range size needed for high bioavailability and the stability required for injectable formulations
Solution Approach 2:
The stable injectable emulsion is achieved through composite material principles by combining cannabinoids with specific ratios of surfactants and co-surfactants. This composite formulation creates a synergistic system where the combined components provide both the ultra-fine droplet size distribution needed for high bioavailability and the interfacial stability required to prevent aggregation during storage and administration
5Reliability
If emulsion droplet size is reduced, then bioavailability increases, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies parameter change principles by systematically controlling multiple formulation variables including surfactant type and concentration, homogenization speed and duration, temperature, and pH. These parameter optimizations enable the consistent production of monodisperse droplet size distributions in the nanometer range, achieving both high bioavailability through small droplet size and manufacturability through reproducible, precise control
Solution Approach 2:
The invention incorporates feedback mechanisms by using real-time monitoring of droplet size distribution during the emulsification process and adjusting formulation parameters accordingly. This feedback-controlled approach ensures consistent production of picometer-range droplets with narrow size distribution, balancing the need for high bioavailability with the practical requirements of manufacturing precision and reproducibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pico-emulsion achieves significantly enhanced bioavailability and exhibits potent antibiotic properties against gram-negative bacteria, overcoming resistance and providing rapid therapeutic effects.
Implementation Method 1
combining one or more cannabinoid isolates with a specific surfactant (polysorbate 80 with HLB 15) is used to create a stable cannabinoid pico-emulsion
Implementation Method 2
ensuring stability through precise surfactant saturation and sonication
Data Source
AI summary
A novel process of creating a cannabinoid pico-emulsion resulting in a sterile and injectable cannabinoid emulsion with increased bioavailability and antibiotic characteristics, and the resulting novel cannabinoid pico-emulsion, for the purpose of treating a wide variety of medical condition in both human and animals.